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Summary
Background Cancer risk following long-term exposure to systemic immunomodulatory therapies in patients with psoriasis is possible. Objectives To assess a dose-response relationship between cumulative length of exposure to biological therapy and risk of cancer. Methods Four national studies (a healthcare database from Israel, and prospective cohorts form Italy, Spain and the U.K. and Republic of Ireland) collaborating through Psonet (European Registry of Psoriasis) participated in these nested casecontrol studies, including nearly 60 000 person-years of observation. 'Cases' were patients who developed an incident cancer. Patients with previous cancers and benign or in situ tumours were excluded. Four cancer-free controls were matched to each case on year of birth, sex, geographic area and registration year. Follow-up for controls was censored at the date of cancer diagnosis for the matched case. Conditional logistic regression was performed by each registry. Results were pooled using random-effects meta-analysis. Results A total of 728 cases and 2671 controls were identified. After matching, differences between cases and controls were present for the Charlson Comorbidity Index in all three registries, and in the prevalence of previous exposure to psoralen-ultraviolet A and smoking (the British Association of Dermatologists Biologic Interventions Register only). The risk of first cancers was not significantly associated with cumulative exposure to biologics (adjusted odds ratio per year of exposure 1Á02, 95% confidence interval 0Á92-1Á13). Results were similar if squamous and basal cell carcinomas were included in the outcome. Conclusions Cumulative length of exposure to biological therapies in patients with psoriasis in real-world clinical practice does not appear to be linked to a higher risk of cancer after several years of use.
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What's already known about this topic?
• Systemic therapies, including biologics, are widely prescribed for patients with moderate-to-severe psoriasis.
• As a result of the immunomodulatory mechanism of biological therapies for psoriasis it is hypothesized that long-term exposure to them may increase the risk of developing cancer.
What does this study add?
• This study suggests that, in current clinical practice, the treatment of patients with psoriasis with biologics is not associated with an increased risk of cancer in the medium term, after a few years of use and latency.
• Given the heterogeneity of the data sources and methodological limitations, it remains unclear if use of biologics may be associated with an increased (albeit small) risk of certain cancer subtypes.
Since the introduction of biological therapy for treating moderate-to-severe psoriasis, some concerns remain about their possible long-term safety. As immunomodulatory drugs, they could theoretically increase the risk of cancer in patients. Previous data, including spontaneous reports, data from clinical trials and observational studies, gave inconclusive results. A recent systematic review provided signals of an increased cancer risk in all patients with psoriasis and in those exposed to anti-tumour necrosis factors (TNFs) [particularly linked to squamous cell carcinoma (SCC)], but the increased risk might be because of inadequate control of key confounding factors (ultraviolet exposure, previous cancers and smoking) or use of historic controls. [1] [2] [3] Detecting an increased risk of cancer is difficult as it is a rare outcome and most studies are underpowered to detect small increases in risk, especially if there is a need to control for confounding as in observational studies. A long latency time to the development of cancer adds to the difficulty of answering this question. Patients who are immunosuppressed, such as those who undergo organ transplants, have an elevated incidence of cancers in the years following surgery with complex patterns of incidence over time, most showing an early increase of risk and remaining over time. 4, 5 Registries included in Psonet, a network of pharmacovigilance cohorts and healthcare databases investigating the safety of biological therapy in patients with moderate-tosevere psoriasis, have been collecting data for more than 6 years; it might now be possible to detect whether there is an increased risk of cancer. Previous studies have shown that single registries are underpowered to estimate risks of this magnitude, 1 which highlights the need for combining the results of several studies. 6 Our aim was to describe if, in patients with psoriasis requiring systemic therapy, there is a dose-response effect linking cumulative exposure to biologics with a higher risk of cancer.
Materials and methods

Psonet network and participating registries
Psonet comprises independent pharmacovigilance registries and healthcare databases that collaborate to investigate the long-term safety and effectiveness of biological and systemic therapies in patients with moderate-to-severe psoriasis. Four Psonet studies provided data for this study: The British Association of Dermatologists Biologic Interventions Register (BADBIR), the Spanish Registry of Systemic Therapy in Psoriasis (BIOBADADERM), the Clalit Health Service database and the Italian Registry of Systemic Therapy in Psoriasis (Psocare). Individual data sharing was not feasible because of data ownership restrictions and administrative differences in the databases. All of them have been previously described. [6] [7] [8] [9] Briefly, BADBIR, BIOBADADERM and Psocare are prospective pharmacovigilance registries of patients with psoriasis receiving biological and/or systemic therapies followed-up during their healthcare visits or at least once a year. We used a nested case-cohort study as it has advantages for the study of cancer 10 and allowed for homogeneous analysis in all substudies given the differences in design and the low number of outcomes. Given that controls sampling was time matched and cases incident, the odds ratio is an unbiased estimate of the rate ratio.
11,12
Defining cases and control groups
Nested case-control studies within each registry were used to determine the risk of cancer associated with cumulative exposure to biological therapy. BADBIR, BIOBADADERM and Psocare used Medical Dictionary for Regulatory Activities coding to classify tumours; Clalit used the tenth revision of the International Classification of Diseases. BADBIR also links in to NHS Digital Cancer data. Case participants were identified as patients with incident cancers excluding those with a history of cancer, and benign and in situ tumours. All cases were reviewed by each participating group to ensure exclusion of benign and in situ tumours followed by a masked review by two clinicians of the Psonet group (I.G.-D. and L.N.). Patients with basal cell carcinoma (BCC) and SCC were not included in the main dataset (MD) for analysis but were included in two sensitivity analyses (MD + SCC; MD + SCC + BCC; summarized in Table S1 ; see Supporting Information). Up to four cancer-free patients in each cohort were matched to each case participant using closest match to year of birth, sex, registration hospital or health area (all registries) and year of entry in the cohort (BADBIR, BIOBADA-DERM, Psocare). These criteria were selected as they were common to each registry and because they might fulfil the requirements of confounders: being associated with cancer and exposure and not in the causal pathway. Year of entry was included to maximize matching on follow-up time and possibly latency between cases and controls. Due to data ownership issues, it was not possible to provide a breakdown of the number of patients with different types of cancer outside of the preagreed SCC and BCC sensitivity analyses for each registry.
Exposure to systemic therapies
Exposure to biological therapies, methotrexate and ciclosporin were calculated as cumulative years of exposure by totalling the person-years of follow-up for each therapy from initiation to stop or censor (date of cancer diagnosis for case participants and their matched controls). Exposure measurement was similar in the case and control groups, and was registered before the study outcome. All biological drugs currently used for psoriasis were grouped because most patients have received several different biologics and, given the long latency (cancer is linked to a drug if the patient was ever exposed to it), 13 it is not possible to link the outcome to any single drug.
We used cumulative length of exposure aiming to detect a dose-response effect to provide more power and strengthen the potential causality of the association.
Confounders
Other expected confounders included in the regression models were: cumulative years of exposure to methotrexate and ciclosporin; duration of psoriasis (years from diagnosis to censor); smoking status; prevalence or length of exposure to phototherapy; and the modified Charlson Comorbidity Index (CCI). Unlike the estimate of risk associated with main exposure, these estimates cannot be considered to represent total effects of these variables, but effects after considering the effect of biologics in cancer.
14 Calculation of lifetime exposure to conventional systemic drugs was calculated by adding the time of exposure while in the cohort and the description of length of exposure that patients gave at entry in the cohort, excluding BADBIR where only prospective exposures were available. Data on previous exposure to phototherapy had variable accuracy as described in Table 1 .
The CCI is a good measure of health resources use and health status. The CCI is robust to modifications as several variants have been used producing similar results. 15 CCI acts like propensity scores, and it has been shown in Cox models that adding the individual components to the model produces minimum improvement over the use of CCI. 16 In this study each registry calculated the CCI on the available variables, excluding previous cancers: BADBIR and Clalit had data on the 17 variables that make the index, Psocare on 16 and BIOBA-DADERM on 11.
Single registry analyses and combined results
Unit of analysis were patients and the first tumour was considered as the outcome. Missing variables were dealt with as described in Table 1 Each centre produced three models: a model with overall cumulative exposure to biologics (raw effect), one adjusting for lifetime cumulative exposure to methotrexate and ciclosporin and a final fully adjusted model including all confounders (Table S1 ; see Supporting Information). Using this method had advantages over commonly used time-based methods, as these give more weight to the time between exposure and outcome than to the cumulative level of exposure. However, a cancer that is very close to a short exposure is unlikely to be because of it, but a cancer that takes place long after an intense exposure is more likely to be because of the exposure. Sensitivity analyses were performed reproducing the same analysis on a population that included SCC among the tumours, and a second with SCC and BCC. The number of SCC did not allow for risk assessment of this tumour type. Pathology reports for skin cancer are not available in the Clalit database, so this group could not run sensitivity analyses. Meta-analysis of these results using a random-effects model was the main outcome of the study.
Results
Characteristics of participating registries and patients
The characteristics of the studies and patients enrolled in the four participating substudies are described in Table 1 . The overall study population consisted of 27 376 patients and 58 978 person-years of follow-up. For the main result we had data on 579 cancer cases and 2671 matched controls. Regarding specific cancer types, we had data for Italy, Spain and U.K. and Republic of Ireland, with a total of 41 cases of SCC and 108 cases of BCC. Before matching, in the overall populations, individuals with cancer were older, with higher CCI and longer duration of follow-up (Table 2) . Multiple tumours by patient were uncommon (Table S2 ; see Supporting Information). Patients in the BADBIR were more likely to have been exposed to psoralen-ultraviolet A therapy (PUVA). There were no significant differences in the length of exposure to biologics between the case and control groups. After matching, differences between those in the case and control groups were present: the prevalence of previous exposure to PUVA and smoking in the U.K. and Republic of Ireland and in the CCI in the U.K. and Republic of Ireland, Spain and Italy (Table 2) .
Results from multivariable analyses and meta-analysis
Multivariable analysis did not show signs of confounding, as main estimates (Table S3 ; see Supporting Information) did not show changes with progressive adjustment (Fig. 1) . None of the within-registry risk estimates (raw or adjusted) showed a significantly increased risk of cancer per cumulative year of exposure to biologics. Results were homogeneous (I 2 of the fully adjusted model: 34Á5%, 3Á5% and 0% for the other models) and the pooled adjusted odds ratio of cancer per year of exposure to biologics was 1Á02 (95% confidence interval 0Á92-1Á13) (Fig. 1) .
The results in the sensitivity analyses, that included analysis with BCC and SCC, were unmodified and nonsignificant (Fig. 2) . We checked in the BIOBADADERM dataset that matching on year of entry into the cohort did not lead to relevant changes in the results.
Discussion
Cumulative length of exposure to biologics was not associated with the risk of developing cancers, even after controlling for the effect of age, sex, location, previous exposure to methotrexate, ciclosporin and phototherapy, duration of psoriasis and comorbidities. Within-registry comparisons gave homogeneous results.
This study has advantages, such as being more representative of clinical practice than clinical trials and generalizable to similar settings. 17 We have measured risks on the medium term with several years of median follow-up. BADBIR, BIOBA-DADERM and Psocare are prospective studies cohorts. BADBIR and BIOBADADERM are likely to represent clinical practice in the U.K. and Republic of Ireland, and Spain, whereas the Clalit Health Services database and Psocare represent populationbased data. Having similar results for all measures of risk in different settings and with different methods reinforces the robustness of our results. Limitations of this study include that it is observational, and uncontrolled confounding could occur. 18 As controlling for well-known important confounders did not change our results, it seems unlikely that other minor confounders would have important effects. Measurement error in some confounders (smoking, previous exposure to immunosuppressive drugs), if nonrandom, could lead to bias. Against this possibility is that the error should vary among participating registries, and estimates are similar.
All biological drugs may not have comparable associated risks of cancer. With a number of outcomes per study ranging from 52 to 269, we lacked adequate power to detect and compare risk between individual drugs. Furthermore, given the long latency in cancer after exposure and the multiple exposures to different biologics for patients with psoriasis it might not be possible to link cancer to single drugs. Differences in risks among biologics remain to be studied.
Another limitation is that we have considered lifetime exposure to biologics without taking into account that different latency periods might act as effect modifiers. Matching on date of entry in the cohorts could partially diminish this issue but could also lead to overmatching. We have checked in the BIO-BADADERM data that this matching did not affect results. As our data describe limited follow-up and latencies, it is still possible that a risk after longer periods of exposure and latencies exists.
Exposure to biological drugs might not increase the risk of all cancers, but only some, such as lymphoma or SCC, and merging them all might hide the risk of these few cancers. However, our study is not powered enough to detect increases in risks of lymphoma, SCC or any single type of cancer, and data ownership issues limited further analysis for this study. Further investigation of the types of cancers that develop following exposure to immunosuppressive antipsoriatic therapies in the studies contributing to this meta-analysis is needed. These studies are also affected by prescription bias: patients with a higher risk of cancer could be less likely to be prescribed biologics. However, we do not think that this limitation is relevant, as after excluding patients with previous 
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0Á30
Data are mean AE SD unless otherwise specified. There is missing data for some variables (see Table 1 ). BIOBADADERM, Spanish Registry of Systemic Therapy in Psoriasis; BADBIR, The British Association of Dermatologists Biologic Interventions Register; Psocare, Italian Registry of Systemic Therapy in Psoriasis; NA, not applicable; PUVA, psoralen-ultraviolet A therapy.
cancer it is unlikely that doctors can predict the risk of cancer in most patients by factors different from those controlled for (age and CCI). Merging data from multiple registries increased the statistical power of our study. The most likely estimate in agreement with our data is an unmodified risk of cancer in patients with systemically treated psoriasis, linked to the use of biologics for a few years. More conservatively, by considering the upper 95% confidence interval of odd ratios, our data are compatible with a maximum increased risk of cancer of about 13% per year of therapy. Currently it is unclear what the maximum clinically acceptable increase in risk of cancer is in this patient group.
A recent systematic review concluded that previous studies do not suggest an increased risk of cancer in patients treated with biologics, except for a possible link between nonmelanoma skin cancer (NMSC) and anti-TNF exposure. However, previous results are limited because of the use of historic or general population comparator groups and lack of adjustment for highly relevant confounding factors such as prior phototherapy. Our study uses concurrent controls with psoriasis and adjusts for main confounders. The number of cancers in our data and data ownership limitations did not allow for analysis on any specific tumour to be done.
The Psoriasis Longitudinal Assessment and Registry study was industry promoted and published results based on half the number of cancer cases in our study. 19 They excluded NMSC from their result and linked cancer to a drug only if patients received it within the year before cancer diagnosis. Their main outcome was an increased risk of cancers in patients exposed to anti-TNF for more than 1 year, but this result depends on the method used to link drug and outcome. In this study with centres from several continents, pooling all data might lead to confounding, as exposure to therapy and outcome (cancer risk) can show geographic variation. Our study is based on more valid within-country comparisons, includes results for NMSC and aims to describe a dose-effect relationship with all biologic exposure, as we believe that it is not possible to link the outcome to a single drug. Taken together, data from our registries including nearly 60 000 person-years of observation indicate that cumulative exposure to biologics in patients with psoriasis in real-world clinical practice is not associated with an overall higher risk of cancer in the medium term, after several years of use and latency. Given the heterogeneity of the data sources and methodological limitations, it remains unclear if use of biologics, or only some of them, may be associated with an increased (albeit small) risk of certain cancer subtypes. Muñoz, M. Onteniente, F. Peral, R. Rivera, D. Ruiz-Genao, J.L. Sanchez Carazo, E. Segovia and R. Torrado.
